Physician profile
Nicole E Back
NPI 1134672116
$2,187.48
in general payments reported to CMS, 2019-2025
23 companies · $709 in 2025
The $709 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $318 · 2023: $427 · 2024: $539 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $297.84 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $247.70 | 2021-2025 | |
| Janssen Biotech, INC. | $235.93 | 2023-2025 | Talvey, Balversa, Erleada |
| Seagen INC. | $208.64 | 2021-2023 | Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $187.05 | 2024-2025 | Fruzaqla, Iclusig, Livtencity |
| Genzyme Corporation | $167.27 | 2025 | |
| Merck Sharp & Dohme LLC | $138.99 | 2022-2025 | Keytruda |
| Genentech USA, INC. | $128.91 | 2023 | Tecentriq |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $82.60 | 2023-2024 | Libtayo |
| Springworks Therapeutics, INC. | $60.81 | 2024 | Ogsiveo |
| Eisai INC. | $46.05 | 2024-2025 | |
| Pfizer INC. | $40.85 | 2024 | |
| Array Biopharma INC | $30.16 | 2025 | Braftovi |
| Jazz Pharmaceuticals INC. | $30.12 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $29.78 | 2025 | Voraxaze |
| Daiichi Sankyo INC. | $28.71 | 2025 | Vanflyta |
| Exelixis INC. | $23.08 | 2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $22.49 | 2024 | |
| Abbvie INC. | $21.95 | 2025 | |
| Pharmacosmos Therapeutics INC. | $21.11 | 2024 | Cosela |
| Kyowa Kirin, INC. | $19.59 | 2024 | Poteligeo |
| Beigene USA, INC. | $17.86 | 2024 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Back listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.